| Item Type | Name |
|
Concept
|
Patient Reported Outcome Measures
|
|
Concept
|
Patient Participation
|
|
Concept
|
Patient Selection
|
|
Concept
|
Patient Outcome Assessment
|
|
Concept
|
Patient Acuity
|
|
Academic Article
|
Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients.
|
|
Academic Article
|
Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers.
|
|
Academic Article
|
Clinical trials for the antiphospholipid syndrome.
|
|
Academic Article
|
Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome.
|
|
Academic Article
|
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
|
|
Academic Article
|
Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus.
|
|
Academic Article
|
Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus.
|
|
Academic Article
|
Clinical trials for lupus--are we there yet?
|
|
Academic Article
|
Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies.
|
|
Academic Article
|
Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis.
|
|
Academic Article
|
Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients.
|
|
Academic Article
|
25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort.
|
|
Academic Article
|
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.
|
|
Academic Article
|
Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.
|
|
Academic Article
|
Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls.
|
|
Academic Article
|
Pathways of impending disease flare in African-American systemic lupus erythematosus patients.
|
|
Academic Article
|
Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.
|
|
Academic Article
|
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.
|
|
Academic Article
|
Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus.
|
|
Academic Article
|
The Spectrum of Health Domains Important to Lupus Patients Early Development of a Disease Activity Patient Reported Outcome.
|
|
Academic Article
|
Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity.
|
|
Academic Article
|
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus.
|
|
Academic Article
|
Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome.
|
|
Academic Article
|
Inhibition of methotrexate-induced rheumatoid nodulosis by colchicine: evidence from an in vitro model and regression in 7 of 14 patients.
|
|
Academic Article
|
Severe guillain-barre-like peripheral neuropathy in a patient with systemic lupus erythematosus: recovery after two separate accidental burn injuries.
|
|
Academic Article
|
Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease.
|
|
Academic Article
|
ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry.
|
|
Academic Article
|
Bone marrow edema is the most specific finding for rheumatoid arthritis (RA) on noncontrast magnetic resonance imaging of the hands and wrists: a comparison of patients with RA and healthy controls.
|
|
Academic Article
|
The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
|
|
Academic Article
|
Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
|
|
Academic Article
|
A 2014 update on the management of patients with systemic lupus erythematosus.
|
|
Academic Article
|
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE).
|
|
Academic Article
|
Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
|
|
Academic Article
|
Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results.
|
|
Academic Article
|
Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab.
|
|
Academic Article
|
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study.
|
|
Academic Article
|
Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
|
|
Academic Article
|
Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study.
|
|
Academic Article
|
Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies.
|
|
Academic Article
|
Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort.
|
|
Academic Article
|
Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE.
|
|
Academic Article
|
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
|
|
Academic Article
|
B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.
|
|
Academic Article
|
Disease-specific patient reported outcome tools for systemic lupus erythematosus.
|
|
Academic Article
|
Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.
|
|
Academic Article
|
Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells.
|
|
Academic Article
|
Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study.
|
|
Academic Article
|
Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus.
|
|
Academic Article
|
Low frequency of flares during pregnancy and post-partum in stable lupus patients.
|
|
Academic Article
|
SR proteins are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes.
|
|
Academic Article
|
Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance.
|
|
Academic Article
|
Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group.
|
|
Academic Article
|
Biomarkers relevant to atacicept effects in systemic lupus erythematosus patients.
|
|
Academic Article
|
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
|
|
Academic Article
|
An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA.
|
|
Academic Article
|
Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus.
|
|
Academic Article
|
Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study.
|
|
Academic Article
|
Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.
|
|
Academic Article
|
Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.
|
|
Academic Article
|
Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
|
|
Academic Article
|
Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus.
|
|
Academic Article
|
The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients.
|
|
Academic Article
|
Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial.
|
|
Academic Article
|
Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.
|
|
Academic Article
|
Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.
|
|
Academic Article
|
Selection of a gene for apolipoprotein A1 using autoantibodies from a patient with systemic lupus erythematosus.
|
|
Academic Article
|
High prevalence of antiphospholipid antibodies in patients taking procainamide.
|
|
Grant
|
Polymorphisms of Antiphospholipid Protein Antigens
|
|
Grant
|
SPORADIC MECHANISM OF THE ANTIPHOSPHOLIPID SYNDROME
|
|
Grant
|
SPORADIC MECHANISM OF THE ANTIPHOSPHOLIPID SYNDROME
|
|
Academic Article
|
SARS-CoV-2 vaccines in patients with SLE.
|
|
Academic Article
|
Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
|
|
Academic Article
|
Tissue factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients.
|
|
Academic Article
|
Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies.
|
|
Academic Article
|
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
|
|
Academic Article
|
Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus.
|
|
Academic Article
|
Biological impact of iberdomide in patients with active systemic lupus erythematosus.
|